|Bid||0.00 x 3100|
|Ask||8.71 x 3200|
|Day's range||8.61 - 9.08|
|52-week range||6.25 - 13.76|
|Beta (5Y monthly)||1.50|
|PE ratio (TTM)||2,160.00|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||N/A|
Teva Launches Two Digital Maintenance Inhalers for the Treatment of Asthma in the U.S.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the 52-week, multicenter, randomized, double-blind, parallel group study evaluating monthly or quarterly AJOVY® (fremanezumab-vfrm) injection in adults with chronic migraine (CM) or episodic migraine (EM), were published online ahead of print in Neurology.
Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present new study data on AUSTEDO at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and Psych Congress 2020 Virtual Experience evaluating the long-term efficacy and safety of AUSTEDO in patients with tardive dyskinesia (TD), and the safety and tolerability of AUSTEDO during periods of titration and maintenance in patients with TD.